# Significant Gene Expression Differences in Histologically "Normal" Liver Biopsies: Implications for Control Tissue

Tarik Asselah,<sup>1,2</sup> Ivan Bièche,<sup>2,3</sup> Ingrid Laurendeau,<sup>2</sup> Michelle Martinot-Peignoux,<sup>1</sup> Valerie Paradis,<sup>4</sup> Dominique Vidaud,<sup>2,3</sup> Dominique-Charles Valla,<sup>1</sup> Pierre Bedossa,<sup>4</sup> Patrick Marcellin,<sup>1</sup> and Michel Vidaud<sup>2,3</sup>

Gene expression technologies allow the analysis of gene networks whose expression is associated with specific pathological conditions compared with normal tissue. We hypothesized that histologically normal tissue obtained in different ways (percutaneous or surgical liver biopsies), usually used as normal controls in gene expression studies, could have different gene expression patterns. Group A comprised percutaneous liver biopsies in 14 patients with mildly elevated alanine aminotransferase in whom all causes of liver disease had been ruled out. Group B comprised 14 surgical liver biopsies of nontumoral livers. All 28 specimens were histologically normal. Real-time quantitative reverse-transcription polymerase chain reaction were used to compare the messenger RNA expression of 240 selected genes in these two groups. Expression of 26 of the 240 genes was significantly different between groups A and B; 23 genes were upregulated in group A, while three were down-regulated in group B. The most notable changes occurred in the inflammatory response family genes. Eight genes discriminated perfectly between groups A and B: seven up-regulated genes (PAI1, THBS1, IL8, PTGS2, CXCR4, JUN, and FOS), and one down-regulated gene (IHH). In chronic hepatitis C liver samples, a lower or higher expression of a IL8 was found depending on whether the controls were obtained percutaneously or surgically. Conclusion: Our study demonstrates that histologically normal liver tissue obtained in two different ways (percutaneous or surgical) has different gene expression patterns emphasizing the importance of an adequate selection of histologically normal controls to prevent discordant results in gene expression studies. (HEPATOLOGY 2008;48:953-962.)

ene expression profiling technologies are used to analyze gene networks whose expression is associated with specific pathological conditions compared with normal tissue.<sup>1</sup> For instance, in 1999, the

high expression of a specific group of genes was identified in highly proliferative breast tumor cells that were compared with normal breast tissue samples.<sup>2</sup>

The development of effective tools for large-scale gene expression analysis has already provided new insights into the involvement of gene networks and regulatory pathways in various tumoral processes.<sup>3</sup> Complementary DNA microarrays can be used to test the expression of thousands of genes at once, while real-time reverse-transcription polymerase chain reaction (RT-PCR) offers more accurate and quantitative information on smaller numbers of selected candidate genes.<sup>4-6</sup>

We hypothesized that the histologically normal tissue usually used as normal controls in gene expression studies obtained in two different ways (that is, percutaneous or surgical liver biopsies), might have different gene expression patterns. We suspected that an acute gene response might be observed during surgery because of aggression and stress, despite the absence of any macroscopic injury. To confirm this hypothesis, real-time quantitative RT-PCR was used to quantify the messenger RNA (mRNA)

Abbreviations: AUC, area under the curve; Ct, cycle threshold; HCV, hepatitis C virus; Hh, Hedgehog; mRNA, messenger RNA; PAI-1, plasminogen activator inhibitor-1; PCR, polymerase chain reaction; ROC, receiver operating characteristic; RT-PCR, reverse-transcription polymerase chain reaction.

From <sup>1</sup>Service d'Hépatologie & Institut National de la Santé et de la Recherche Médicale (INSERM) U733, CRB3, Université Paris Diderot, Assistance Publique-Hôpitaux de Paris, Hôpital Beaujon, Clichy, France; <sup>2</sup>INSERM, U745, Paris, France; Université René Descartes, Paris, France; <sup>3</sup>Service de Génétique Moléculaire, Hôpital Beaujon, Clichy, France; and <sup>4</sup>Service d'Anatomie Pathologique, Hôpital Beaujon, Clichy, France.

Received March 29, 2008; accepted April 30, 2008.

Supported by Agence Nationale de Recherche sur le Sida et les Hépatitites virales (ANRS) and Ministère de l'Enseignement Supérieur et de la Recherche.

Address reprint requests to: Tarik Asselah, M.D., Ph.D., Service d'Hépatologie, Hôpital Beaujon, 92110, Clichy, France. E-mail: tarik.asselah@bjn.aphp.fr; fax: (33)-1-47-30-94-40.

Copyright © 2008 by the American Association for the Study of Liver Diseases. Published online in Wiley InterScience (www.interscience.wiley.com). DOI 10.1002/hep.22411

Potential conflict of interest: Nothing to report.

expression of a large number of selected genes in pooled A (histologically normal tissue obtained percutaneously) specimens compared with pooled B (histologically normal tissue obtained surgically) specimens. The expression level of 240 genes known to be involved in various cellular and molecular mechanisms associated with response to stress was examined. We especially focused on the expression of genes related to early stress response, hypoxia, and inflammation.<sup>7-12</sup>

Genes of interest were further investigated in 14 individual group A specimens compared with 14 individual group B specimens. We then investigated whether the choice of histologically normal controls could lead to discordance or misinterpretation of specific pathological conditions such as chronic hepatitis C.

## **Materials and Methods**

We selected liver samples on the basis of a histologically normal pattern: no portal or lobular inflammation and/or necrosis; absence of portal, central, or perisinusoidal fibrosis; and no other significant abnormal features (steatosis <5%, no iron overload, no ballooning or liver cell clarification, no cholestasis or bile duct lesion).

#### Group A

Group A comprised percutaneous normal liver biopsy specimens, obtained from 14 adults with mildly elevated serum alanine aminotransferase activity addressed to Beaujon Hospital (Clichy, France), in whom all causes of liver disease had been ruled out (medication, alcohol, chronic viral hepatitis, autoimmune processes, and metabolic disease). In these adults, liver biopsies were performed percutaneously under local anesthesia. A transparietal biopsy of a normal liver is illustrated in Fig. 1A.

#### Group B

Surgical liver biopsies of nontumoral livers were obtained from 14 adults during operations for liver metastasis of colorectal cancer (n = 7) or benign liver tumors (n = 7) under systemic/general anesthesia. For the purpose of this study, we sampled tissue fragments at least 3 cm from the nearest metastasis. Neither fragment showed portal distorsion or expansion, ductular proliferation, or cholestasis that could suggest a mass effect. A surgical biopsy of a normal liver is illustrated in Figure 1B.

All 28 liver tissue specimens from group A and group B were histologically normal (absence of inflammation, fibrosis, and pathological pattern).

For all cases, one fragment was frozen and used for mRNA extraction and another was formalin-fixed and



Fig. 1. (A) Transparietal biopsy of normal liver. The normal portal tract and central vein are shown. Hepatocytes are arranged in regular trabeculae (hematoxylin-eosin staining; magnification  $\times 25$ ). (B) Surgical sample of normal liver. The lobular architecture is well-preserved; the normal portal tract is present in the center (hematoxylin-eosin staining; magnification  $\times 25$ ).

paraffin-embedded. All these samples were carefully reviewed by two liver pathologists and considered normal.

#### Chronic Hepatitis C Patients

Percutaneous liver biopsy specimens obtained from 55 chronic hepatitis C patients, selected from a cohort of untreated patients with chronic hepatitis C followed at Beaujon Hospital (Clichy, France), were graded and staged (Metavir),<sup>13</sup> and the gene expression was studied (A1F1 [n = 11], A2F1 [n = 9], A1F2 [n = 10], A2F2 [n = 10], A2F3 [n = 15]).

The study was approved by the local ethics committee and conformed to the 1975 Declaration of Helsinki. All patients gave informed consent prior to liver biopsy.

### Large-Scale Real-Time RT-PCR

*Theoretical Basis.* Reactions are characterized by the point during cycling when amplification of the PCR product is first detected, rather than the amount of PCR product accumulated after a fixed number of cycles. The larger the starting quantity of the target molecule, the earlier a significant increase in fluorescence is observed. The parameter Ct (threshold cycle) is defined as the fractional cycle number at which the fluorescence generated by SYBR green dye-amplicon complex formation passes a fixed threshold above baseline. The increase in fluorescent signal associated with exponential growth of PCR products is detected by the laser detector of the ABI-Prism 7900 Sequence Detection System (PerkinElmer Applied Biosystems, Foster City, CA), using PE Biosystems analysis software according to the manufacturer's instructions.

The precise amount of total RNA added to each reaction mix (based on optical density) and its quality (that is, lack of extensive degradation) are both difficult to assess. We therefore also quantified transcripts of two endogenous RNA control genes involved in two cellular metabolic pathways, namely *TBP* (Genbank accession number NM\_003194), which encodes the TATA box-binding protein (a component of the DNA-binding protein complex TFIID), and *RPLP0* (also known as 36B4 [Genbank accession number NM\_001002]), which encodes human acidic ribosomal phosphoprotein P0. Each sample was normalized on the basis of its *TBP* (or *RPLPO*) content.

Results, expressed as N-fold differences in target gene expression relative to the *TBP* (or *RPLPO*) gene, and termed Ntarget, were determined as Ntarget =  $2^{\Delta Ct_{sample}}$ , where the  $\Delta Ct$  value of the sample was determined by subtracting the average Ct value of the target gene from the average Ct value of the *TBP* (or *RPLPO*) gene.

The Ntarget values of the samples were subsequently normalized such that the median value of the percutaneous normal liver specimen Ntarget was 1.

**Primers and Controls.** We suspected that, during surgery, as during aggression or stress, an acute gene response would be observed despite the absence of macroscopic injury. Based on a study of the literature describing early gene expression changes during aggression (associated with stress), we selected 240 genes involved in various cellular and molecular mechanisms associated with response to stress and during hepatic stellate cell activation, because these cells participate in the remodeling of injured livers.<sup>7-12</sup> These genes encode proteins involved in the immune response, extracellular remodeling, oxidative stress, signal transduction pathways, cell cycle control, apoptosis, angiogenesis, interferon signaling, and so

forth. Approximately 10 to 20 genes were selected per pathway (Fig. 2).

Primers for *TBP*, *RPLP0*, and the 240 target genes were chosen with the assistance of the Oligo 5.0 computer program (National Biosciences, Plymouth, MN).

We conducted searches in the dbEST and nr databases to confirm the total gene specificity of the nucleotide sequences chosen as primers and the absence of single nucleotide polymorphisms. In particular, the primer pairs were selected to be unique relative to the sequences of closely related family member genes or of the corresponding retro-pseudogenes. To avoid amplification of contaminating genomic DNA, one of the two primers was placed at the junction between two exons, if possible. In general, amplicons were between 70 and 120 nucleotides long. Gel electrophoresis was used to verify the specificity of PCR amplicons.

For each primer pair, we performed no-template control and no-RT control (RT-negative) assays, which produced negligible signals (usually >40 in Ct value), suggesting that primer-dimer formation and genomic DNA contamination effects were negligible.

**RNA Extraction.** Total RNA was extracted from frozen liver tissue samples using the acid-phenol guanidinium method. The quality of the RNA samples was determined via electrophoresis through agarose gels and staining with ethidium bromide, the 18S and 28S RNA bands being visualized under ultraviolet light.

**Complementary DNA Synthesis.** Total RNA was reverse-transcribed in a final volume of 20  $\mu$ L containing 1× RT buffer (500  $\mu$ M each deoxyribonucleotide triphosphate, 3 mM MgCl<sub>2</sub>, 75 mM KCl, 50 mM Tris-HCl [pH 8.3]), 20 U RNasin ribonuclease inhibitor (Promega, Madison, WI), 10 mM dithiothreitol, 100 U Superscript II ribonuclease H reverse transcriptase (Invitrogen, Cergy Pontoise, France), 3  $\mu$ M random hexamers (Pharmacia, Uppsala, Sweden), and 100 ng total RNA. The samples were incubated at 20°C for 10 minutes and 42°C for 30 minutes, and reverse-transcription was inactivated by heating at 99°C for 5 minutes and cooling at 5°C for 5 minutes.

**PCR** Amplification. All PCR reactions were performed using an ABI-Prism 7900 Sequence Detection System (PerkinElmer Applied Biosystems) and the SYBR Green PCR Core Reagents kit (PerkinElmer Applied Biosystems). Ten microliters of diluted sample complementary DNA (produced from 2 ng of total RNA) was added to 15  $\mu$ L of the PCR master mix. The thermal cycling conditions comprised an initial denaturation step at 95°C for 10 minutes, and 50 cycles at 95°C for 15 seconds and 65°C for 1 minute.

FN1     Florescrint     Florescrint<	Extracellular matrix :		Signal transduction :		Cell cycle :		Apoptosis :		
<ul> <li>HAS2 Hydroman privates 2</li> <li>HSNP Privaceta</li> <li>HSNP Pr</li></ul>	-FN1	Fibronectin 1	-CAV1	Caveolin 1	-CCND1	Cyclin D1	-AKT1	AKT1 oncogene	
-TTM     Virnextin     -FYN     FYN     FYN moscene     -BX     Additional perton     -BXX     BC2 arrangetin       -FES     Hagenesses     -BXX     Machine perton     -BXX     BC2 arrangetin     -BXX     BC2 arrangetin       -TH8S     Thrombosondont-1     -BXX     See perton     -BXX     BC2 arrangetin     -BXX     BC2 arrangetin       -SAX     Desmoglen     -FXX     FXX     Color     Color     Color     -BXX     BC2 arrangetin       -SAX     Desmoglen     -FXX     FXX     Color     Advit     Advit     BC2 arrangetin     -BXX     BC2 arrangetin       -SAX     Desmoglen     -FXX     Color     Advit     Protein insection     -Advit     BC2 arrangetin     -BXX     Color     -BXX     BC2 arrangetin     -BXX     -BXX     BC2 arrangetin     -BXX     -CXX     -CX	-HAS2	Hyaluronan synthase 2	-PRNP	Prion protein 2	-CCNE1	Cyclin E1	-BCL2	B-Cell lymphoma 2 oncogene	
Hepcrosse       -HCL       Shift Charafforming protein       -HCL       Bit Charafforming protein       -HCL       Bit Charafforming protein         -THSD       Threshold maints       -GSC       See protein       -CDKNB       COK Inditry, p15 protein       -HCL       Bit Charafforming (GL-X)         -THSD       Threshold maints       -HCL       See protein       -CDKNB       COK Inditry, p15 protein       -HCL       Bit CharAfformin       -HCL       -HCL       Bit CharAfformin       -HCL       -HCL <td>-VTN</td> <td>Vitronectin</td> <td>-FYN</td> <td>FYN oncogene</td> <td>-RB1</td> <td>Retinoblastoma</td> <td>-BAX</td> <td>BCL2-associated X protein</td>	-VTN	Vitronectin	-FYN	FYN oncogene	-RB1	Retinoblastoma	-BAX	BCL2-associated X protein	
- SDC1 Syndex 1 - SDC2 Syndex 1 - SDC3	-HPSE	Heparanase	-SHC1	Shc transforming protein	-MDM2	Mdm2 protein	-BAK1	BCL2 antagonist killer-1	
TheBS1       Theomespane       -SOS1       See protein       -SOS1A       See protein       -SOS1A<	-SDC1	Syndecan 1	-GRB2	Growth factor bound protein	-CDKN2B	CDK inhibitor, p15 protein	-BCL2L1	Long isoform. (BCL-XL)	
-CLDM       Claudin 4       -PRICA       Pretrik kinase C alpha       -ABF       p19/AIT pretrie       -BDD       BH3-interacting domain death agenits         -GLDM       Claudin 4       -MARA       Name ancagene       -AGDD4 40       -GADD4 40       -GADA4 40       -GAD4 40       -GAD4 40       -GADA4 40 <t< td=""><td>-THBS1</td><td>Thrombospondin-1</td><td>-SOS1</td><td>Sos protein</td><td>-CDKN2A</td><td>CDK inhibitor, p16 protein</td><td>-BCL2L1</td><td>Short isoform (BCL-XS)</td></t<>	-THBS1	Thrombospondin-1	-SOS1	Sos protein	-CDKN2A	CDK inhibitor, p16 protein	-BCL2L1	Short isoform (BCL-XS)	
-562     Desingelin 2	-CLDN4	Claudin 4	-PRKCA	Protein kinase C alpha	-ARF	p19/AKT protein	-BID	BH3-interacting domain death agonist	
FLG       Plasmingen       +RAS       Ni-Ras monogene       -SRA       Service       -SRA       -SRA       Service       -SRA       -SRA       Service       -SRA	-SG2	Desmoglein 2	-MUC1	Mucin 1	-GADD45A	GADD45 alpha	-HCS	Cytochrome C	
-COLLA1 Collagen, Typs 1, olpha 1 -STAR CollA2 Collagen, Typs 1, olpha 2 -STAR Secreted part, actic cyst -tch Autor for actic cyst -tch Autor	-PLG	Plasminogen	-NRAS	N-Ras oncogene	-SFN	Stratifin	-SMAC	Diable/Smac protein	
-COLLA Collagen, type 1, gibe 2 -SPACe Server de prot. coll, expension activation growth in 1 -ALAL FT2se activating protein 1 -ALAL FT2se activating factor 1 -ALAL FT2se activation 2 -ALAL F	-COL1A1	Collagen, type I, alpha 1	-HRAS	H-Ras oncogene	-MAD2L1	Mitotic arrest deficient like 1	-PDCD8	Apoptosis-inducing factor (AIF)	
-SPARC     Secreted price acidic cyst-rich Matrix proteases : HU     -NHI Muurdihordinin     -NHI Muurdihordinin     -AHI Muurdihordinin	-COL1A2	Collagen, type I, alpha 2	-SSPN	K-Ras oncogene	-TOP2A	Topoisomerase II alpha	-CASP9	Caspase 9	
Article professes : PLAU PLAT       Reframe activating protein 1 PLAU PLAT       Reframe activating protein 1 PLAU PLAT       Reframe activating protein 1 PLAU PLAU PLAU PLAU PLAU PLAU PLAU PLAU	-SPARC	Secreted prot. acidic cyst-rich	-NF1	Neurofibromin	-MKI67	Proliferation-related Ki-67 antigen	-CASP3	Caspase 3	
Matrix proteases :         -RAFI           Ref management (Risking)         -RAFI           Ref management (Risking)         -RAFI           Ref management (Risking)           PLAU           Plaumingen activator, unknown         -RAFI           Ref management (Risking)         -RAFI		. ,	-RASA1	GTPase activating protein 1			-APAF1	Apoptotic protease activating factor 1	
FLAT       Plasmingen activator, urskinse       PIXSR1       PIXSR1       PIXSR2       SR2 actorptic pLO apha       PDF back chain       -VEGF       VEGF VEGF - A         MWP2       Matrix metalloproteinaes 7       SR2 accogen       SR2 accogen       -KTLG       Fiscal PISSR1       PDF back chain       -VEGF VEGF - A       -VEGF VEGF - A         MWP1       MATI-MMP       -KTLGA       Fiscal PISSR       SR2 accogen       -KTLGA       Fiscal PISSR       -KTLGA       Fiscal PISSR1       -KTLGA	Matrix pro	oteases :	-RAF1	Raf oncogene	Growth fo	ctors :	-BIRC5	Survivin	
PLAT       Pisaminegia extrustri, fitsual       PTISCA       PISCA BRC oscience       PTICE       Statution       Angiogenesis:	-PLAU	Plasminogen activator, urokingse	-PIK3R1	PI3K p85 alpha subunit	-PDGEA	PDGE alpha chain			
MWP2         Matrix metalloproteinase 7         -SRC         SRC encogine	-PLAT	Plasminogen activator, tissue	-PIK3CA	PI3K catalytic p110 alpha	-PDGEB	PDGE beta chain (Sis)	Angiogen	esis :	
WWP WWP WWP WWP WWP 	-MMP2	Matrix metalloproteinase 2	-SRC	SRC oncogene	-KITI G	Stem cell factor	-VEGE	VEGE-A	
<ul> <li>MWP3 Matrix metalloproteines 9</li> <li>MWP1 Matrix metalloproteines 1</li> <li>MWP1 Matrix proteases :</li> <li>FINAL Caterin lafba 1</li> <li>FI</li></ul>	-MMP7	Matrix metalloproteinase 7	-PTK2	Focal adhesion kinase (FAK)	-TGFA	Transforming growth factor alpha	-VEGEB	VEGF-B	
MWP14       MT1-MWP      TINABL       C-TINABL       Caterin bipho 1      WEFA      WEFA <t< td=""><td>-MMP9</td><td>Matrix metalloproteinase 9</td><td>-BCAR1</td><td>Cas</td><td>-FGF</td><td>Enidermal arowth factor</td><td>-VEGEC</td><td>VEGF-C</td></t<>	-MMP9	Matrix metalloproteinase 9	-BCAR1	Cas	-FGF	Enidermal arowth factor	-VEGEC	VEGF-C	
-CTNNBI	-MMP14	MT1-MMP	-CTNNA1	Catenin alpha 1	-ADEG	Amphineculin	-VEGED	VEGE-D	
Inhibitors of motrix proteases : SEPENINB Sering proteins inhibitor 21 SEPENINB Sering proteins inhibitor 2412 -SEPENINB Sering proteins 24 -SEPENINB Sering			-CTNNB1	Catenin beta 1	-FREG	Epigeoulin	-FLT1	VEGE recentor 1 (VEGER1)	
<ul> <li>-ESPETINB2 Gening proteinas inhibitor (PAI)</li> <li>-REACI Re C</li> <li>-RAHA Rhe A</li> <li></li></ul>	Inhibitors	of matrix proteases :	-AXIN1	Axin	-NDG1	Neuraculin 1	-KDR	VEGE recentor 2 (VEGER2)	
<ul> <li>Septime 2 denime proteinase initiality (PA2)</li> <li>Septime 2 denime proteinase initiality (PA2)</li> <li>ARHA Rho A</li> <li>TIMPI Times inhibitor 1 of MMP</li> <li>Times inhibitor 2 of MMP</li> <li>Times inhibitor 3 of MMP</li> <li>TIMPA Tissue inhibitor 3 of MMP</li> <li>TIMPA Tissue inhibitor 4 of MMP</li> <li>TIMPA Tissue inhibitor 1 (Bit Carter 4 and the protein 2 derived function 1</li> <li>TIGAG Integrin a0</li> <li>TITEAG Integrin a5</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a7</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a7</li> <li>TITEAG Integrin a7</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a7</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a7</li> <li>TITEAG Integrin a8</li> <li>TITEAG Integrin a6</li> <li>TITEAG Integrin a7</li> <li>TITEAG Integrin a8</li> <li>TITEAG Integrin a8</li> <li>TITEAG Integrin a7</li> <li></li></ul>	_CEDDTNID1	Saning mateinage inhibiton (PAT1)	-ROCK1	Rho-associated protein K 1	-NDG2	Neuregulin 2	-FLT4	VEGE recentor 3 (VEGER3)	
-TIMP2       Transphibitor       1 of MMP       -ARIC       Roc 1         -TIMP2       Tissue inhibitor 3 of MMP       -ARIC       Roc 1       -II.d       Interleakin 1       -ANBPT 2       Anglopsietin 2         -TIMP2       Tissue inhibitor 3 of MMP       -DCC42       Cell division cycle 42       -II.d       Interleakin 1       -ARIC       RMC         -TIMP4       Tissue inhibitor 3 of MMP       -ARIC       Rect       -CC42       Cell division cycle 42	-SERFINDI	Serine proteinuse inhibitor (PAII)	-ARHA	Rho A	-NIDG3	Neuregulin 2	-ANGPT1	Angiongietin 1	
-TIMP2       Tissue inhibito 2 of MMP       -RAC1       Rac 1       -TL6       Interleavin 6 opna         -TIMP3       Tissue inhibitor 3 of MMP       -CC42       Interleavin 10       -TL6A       Interleavin 10         -TIMP4       Tissue inhibitor 4 of MMP       -PAK1       P21/CDC42/RAC1 activated kinese1       -CC4       Glycoport. hormone olpho polypeptide       -FE       -TE       -TE <td>-JERFINDE</td> <td>Tirsue inhibiten 1 of MMP</td> <td>-ARHC</td> <td>Rho C</td> <td>-TI 1 4</td> <td>Interleukin 1 alaba</td> <td>-ANGPT2</td> <td>Angiopoletin 2</td>	-JERFINDE	Tirsue inhibiten 1 of MMP	-ARHC	Rho C	-TI 1 4	Interleukin 1 alaba	-ANGPT2	Angiopoletin 2	
<ul> <li>Titles Tissus inhibitor 3 of MMP</li> <li>Titles inhibitor 3 of MMP</li> <li>Titles inhibitor 3 of MMP</li> <li>Titles inhibitor 4 of MMP</li> <li>Titles inhibitor 4 of MMP</li> <li>Cell adhesion and cell junction :</li> <li>Cold Hydroman receptor (CD44)</li> <li>Hydroman receptor (CD44)</li> <li>Hydroman receptor (RHAMM)</li> <li>Cold Hydroman receptor (RHAMM)</li></ul>	TTMP2	Tissue inhibitor 2 of MMP	-RAC1	Rac 1	-116	Interleukin 6	-TEK	TEK tyrosine kinose (TIE2)	
TimeTissue inhibitor 4 of MMDPAKIp21/CDC42/RACI activated kinaselCorrPaki activated kinaselPaki activated kinasel <td>TTMP3</td> <td>Tissue inhibitor 2 of MMP</td> <td>-CDC42</td> <td>Cell division cycle 42</td> <td>-TL10</td> <td>Interleukin 10</td> <td>-XLKD1</td> <td>Lymph, vessel endoth recentor1 (LYVE1)</td>	TTMP3	Tissue inhibitor 2 of MMP	-CDC42	Cell division cycle 42	-TL10	Interleukin 10	-XLKD1	Lymph, vessel endoth recentor1 (LYVE1)	
<ul> <li>Justice Transcription factors:</li> <li>-VIL2</li> <li>Villia 2 (Ezrin/EMR)</li> <li>-TEFB2</li> <li>-Gel adhesion and cell junction:</li> <li>-CD4</li> <li>Hyaluronan receptor (CD44 Ag)</li> <li>+MMA</li> <li>Hyaluronan receptor (RHAMA)</li> <li>-CGAPTI</li> <li>-CGAPTI</li></ul>	-TTMP4	Tissue inhibitor 4 of MMP	-PAK1	p21/CDC42/RAC1 activated kinase1	-CGA	Glycoprot hormone alpha polypeptide	-HIF1A	Hypoxia-inducible factor 1 alpha	
Cell adhesion and cell junction :       -NF2       Neurofibromin 2 Marlin       -5DF1       CXC chamakine igond 12 (CXC12)       -MDK         -CD44       Hyaluronan receptor (CD44 Ag)       -5TM1XI       Stathmin 1 / Onceprotein 18       -5DF1       CXC chamakine igond 12 (CXC12)       -MDK       -MDK       Muldike (NG672)         -CD41       E-cadherin       -TG6A       Integrin aV       -TG6A       -TG6A       -FG7E       Integrin aV         -TT6A5       Integrin aD       -SST-1       Suppressor crytokine sig 1 (SOC51)       -HGF       Hept corrective tissue growth factor       -TG7E       Tombox receptor (R): PAR1         -TT6B3       Integrin aD       -SST-1       Suppressor crytokine sig 1 (SOC51)       -HGF       -HGF       -TG7E       Connexine tissue growth factor Pato       -SOD1       Superoxyde desmutase 1         -TT6B3       Integrin B3       -TG6A       -TG7E       Tumotor necrespts factor       -TFF8       Tramoforming growth factor Pato       -SOD1       Superoxyde desmutase 1	1 200 4	hasde innorrer 4 of mm	-VIL2	Villin 2 (Ezrin/EMR)	-TGEBP2	TGE binding protein 2	-F3	Tissue factor (TF)	
<ul> <li>Chord Hydrenon receptor (CP4 Ag)</li> <li>Hydrenon recept</li></ul>	Cell adhes	ion and cell junction :	-NF2	Neurofibromin 2 Merlin	-SDF1	CXC chemokine ligand 12 (CXCL12)	-F2R	Thrombin receptor (TR): PAR1	
<ul> <li>-CD44 myduronan receptor (CD44 Ag)</li> <li>-STMNI Staffmin 1 / Oncoprotein 18 -CD41 IC 6CP II (C 6P1as a critotor 1 -IC 6AP1 IC 6P1as a critotor 1 -IC 6AP2 IQ 6Pas a critotor 1 -IC 6AP1 IC 6P1as a critotor 1 -IC 6AP1 IC 6AP1 IC 6AP1 IC 6AP1 IC 6AP1 -IC 6AP1 IC 6AP1 IC 6AP1 IC 6AP1 IC 6AP1 IC 6AP1 IC 6AP1 -IC 6AP1 IC 6AP</li></ul>	Cell uunes	ion and cell junction .	-ILK	Integrin-like kinase	-6PO1	Graf ancogene	-MDK	Midkine (NEGE2)	
Trumk CDH1C-Cadherin E-CadherinIQ 6FPase activator 1 -TEGA1-IQ 6AP 1 [Q 6FPase activator 2 -HM61-IGE Arrow -HBC activator 2 -HBC activator 2 -HBG activator 2 <b< td=""><td>-0044</td><td>Hydiuronan receptor (CD44 Ag)</td><td>-STMN1</td><td>Stathmin 1 / Oncoprotein 18</td><td>-KTSS1</td><td>Kiss_1 metastasis_suppressor</td><td>-SERPINB5</td><td>Serin proteinase inhibitor (Maspin)</td></b<>	-0044	Hydiuronan receptor (CD44 Ag)	-STMN1	Stathmin 1 / Oncoprotein 18	-KTSS1	Kiss_1 metastasis_suppressor	-SERPINB5	Serin proteinase inhibitor (Maspin)	
-Contact       -Cooker       -Cooker       -Cooker       -Cooker       -Cooker       -Cooker       -PROK1       Prokineticin 1 (EG-VR6F)         -TTGAV       Integrin ad       -SSI-1       Suppressor cytokine sig.1 (SOCS1)       -APC       Ademontosis polyposis coli       -TGFB       Transforming growth factor 2       -SOD1       Superoxyde desmutase 1         -TTGAS       Integrin ad       -APC       Ademontosis polyposis coli       -TGFB       Transforming growth factor 2       -SOD1       Superoxyde desmutase 1         -TTGB3       Integrin B1       -APC       Ademontosis polyposis coli       -TGFB       Transforming growth factor 2       -SOD2       Superoxyde desmutase 1         -GTB3       Connexin 63       -TTGAS       Tronsforming growth factor ceptor star       -SOD2       Superoxyde desmutase 1         -GTB1       Connexin 43       -TMSB4X       Trymosin beto 4       -VASF       Vasodilator stimulated Pportein         -GTA1       Connexin 43       -CALD1       Caldesmon 1       -PDFRA       PDF receptor star       -DMT1       -DMMT3A       DNA methyltransferase 1         -SMX2       Snail homolog 1       -CMVC       -CMVC       -ARA       Retinoic X receptor alpha       -PDFRA       PDF receptor       -HLA-C       MHC (class I, C       -HLA-C       -HLAC	-FIMMK	E Codhonin	-IQGAP1	IQ GTPase activator 1	-HGE	Henotocyte growth factor	-THBD	Thrombomodulin	
<ul> <li>HMG1 High mobility group 1</li> <li>HMG1 High mobility group 1</li> <li>Supressor cytokine sig.1 (SOCS1)</li> <li>APC Adenomatosis polyposis coli</li> <li>TFG64 Integrin 05</li> <li>TFG64 Integrin 05</li> <li>Conexin 32</li> <li>Gonexin 43</li> <li>Transforming growth factor 2</li> <li>TGF68 Integrin 05</li> <li>Cytoskeletal :</li> <li>VASP Vasodilator stimulated Pprotein</li> <li>GJB1 Conexin 32</li> <li>Gonexin 43</li> <li>TRAN Troponyosin 1</li> <li>ACTM4 Actinin, alpha 4</li> <li>Treal lyphoma invasion metastasis</li> <li>SNAI2 Snail homolog 1</li> <li>SNAI2 Snail homolog 2 (SUU6)</li> <li>ETV4 E1A enhancer-binding protein</li> <li>CEBPA CCANTreAncer binding protein</li> <li>CEBPA CCANTreAncer binding protein</li> <li>GEBA CCANTreAncer binding protein</li> <li>TCER E Estrogen receptor alpha</li> <li>PPARG Peroxisome prolif activ. receptor y</li> <li>TIN JUND jun D proto-oncogene</li> <li>TUND jun D proto-oncogene</li> <li>TUND jun D proto-oncogene</li> <li>THRA Thyroid hormone receptor beta</li> <li>THRA T</li></ul>	TTGAV	E-Cadherin Integnin gV	-IQGAP2	IQ GTPase activator 2	-HDGE	Henotomo-derived growth factor	-PROK1	Prokineticin 1 (EG-VRGF)	
-176A5       Integrin d5       -SSI-1       Suppressor cytokine sig.1 (SOC51)       -IF2       Fundamina in the source growth factor bact 2       -SOD1       Supproxyde desmutase 1         -176A5       Integrin j3       -XPC       Adenomatosis polyposis coli       -IF2       Transforming growth factor bact 2       -SOD1       Supproxyde desmutase 1         -176B1       Transforming growth factor bact 2       -TFFB1       Transforming growth factor bact 2       -SOD1       Supproxyde desmutase 1         -67B2       Connexin 32       -KFT1       Kaschin in John 4       -KFT1       Fundamina in the source growth factor bact 2       -FUT1       Fucasition in John 4         -67A1       Connexin 33       -FWT1       Tronpomyosin 1       -ACTNA       Actinin, alpha 4       -ACTNA       Actinin, alpha 4       -MET       -DMT1       DNA methyltransferase 1       -DMMT3A       DNA methyltransferase 3       Jeba         -SNA12       Snail homolog 1       -ACTNA       Actinin, alpha 4       -MET       -RET       RET oncogene       -SMAI       -DMT3B       DNA methyltransferase 1       -DMMT3B       DNA methyltransferase 3       Jeba         -SNA12       Snail homolog 1       -ACTNA       Actinin, alpha 4       -RET       RET oncogene       -SMAI       -SMAI       Trest polyleptide       -RET       RET	TTCAL	Integrin dv	-HMG1	High mobility group 1	-CTGE	Connective tissue growth factor			
-APCAdenomators polyposis coli-TGFB1Transforming growth factor beta 1-SOD1Superoxyde desmutase 1-TTGB4Integrin β3-VASPVasodilatator stimulated Pprotein-TGFB1Transforming growth factor beta 2-SOD1Superoxyde desmutase 2-TTGB4Integrin β3-VASPVasodilatator stimulated Pprotein-TGFB1Transforming growth factor beta 2-SOD1Superoxyde desmutase 2-TTGB4Integrin β4-VASPVasodilatator stimulated Pprotein-TMSP4XThymosin beta 4-STA1-SIA1-SIA1Connexin 40-CAL10Caldesmon 1-FDFRAPDFF receptor alpha-SIA11-SIA1-SIA1Connexin 43-TUBBTubulin, beta polypeptide-TTAN 1-T-cell lyphoma invasion metasas 3, alpha-SNA11Snail homolog 1-SIA1CarAr centor eceptors :-TGFB1Transforming growth factor receptor-SIA11Sialyl transferasa 1-SNA12Snail homolog 1-ACTM4Actinin, alpha 4-TUBBTubulin, beta polypeptide-TLA4-FLA4-FLA4-SERPET receptor-SNA12Snail homolog 2(SLU6)-TARARetinoic X receptor alpha-SEB-ERB8-erbb-3-NOS3-NOS3NNOS, neuronal nitric coide synthase 1-SNA12Snail homolog 1-SER-SER-EFREGF receptor (ERBB1)-NOS24-NOS24-NOS3NNOS, neuronal nitric coide synthase 1-SNA12Snail homolog 1-SER-SER-erbb-3-erbb-3-SER-NOS3NNOS, neuronal nitric coide synthase 1 <td>TTGAS</td> <td>Integrin di</td> <td>-SSI-1</td> <td>Suppressor cytokine sig 1 (SOCS1)</td> <td>-IGE2</td> <td>Insulin-like growth factor 2</td> <td>Various (</td> <td>metabolic enzymes) :</td>	TTGAS	Integrin di	-SSI-1	Suppressor cytokine sig 1 (SOCS1)	-IGE2	Insulin-like growth factor 2	Various (	metabolic enzymes) :	
17690       Integrin fig1         177691       Integrin fig1         177691       Integrin fig1         177692       Transforming growth factor beta 2         177693       Integrin fig1         177694       Integrin fig1         177695       Integrin fig1         -17694       Integrin fig3         -17695       Integrin fig3         -17694       Integrin fig1         -67381       Connexin 32         -6741       Caldesmon 1         -6742       Concogene         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -6744       Cacharonez binding protein         -6289       Coccarbo 1 (HNF1)         -FCP1       Hepatic nuclear factor 1 (HNF1)         -FCP1       Hepatic nuclear factor 1 (HNF1)         -JUNB       jun proto-oncogene         -JUND       jun D proto-oncogene         -JUND       jun	TTGAS	Integrin d5	-APC	Adenomatosis polyposis coli	-TGFB1	Transforming growth factor beta 1	-SOD1	Superoxyde desmutose 1	
Trobal Integrin [3]       Cytoskeletal :       -TKBS       <	-116A0	Integrin do			-TGFB2	Transforming growth factor beta 2	-5002	Superoxyde desmutase 2	
112694       Integrin fp3         -17694       Integrin fp3         -6781       Connexin 32         -6774       Connexin 40         -6774       Concogene         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -6774       E1A enhancer-binding protein         -6774       Concogene         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -5NA12       Snail homolog 1         -5NA2       CCAT/F4         -70571       Hepstic nuclear factor 1 (HNF1)         -7071       Hepstic nuclear factor 1 (HNF1)         -7010       jun proto-oncogene         -7UND       jun D proto-	-17683	Integrin pi	Cvtoskele	etal :	-TNF	Tumor necrosis factor	-FUT1	Fucasyl transferase 1	
1.100// Image       Timesin 26       -TMSB4X       Thymesin beta 4       -TMSB4X       Thymesin beta 4       -TMSB4X       Thymesin beta 4       -TMSB4X       Thymesin beta 4       -TMSB4X       -TMSB4X       Thymesin beta 4       -TMSB4X       -TMSB4X       Thymesin beta 4       -TMSB4X       -TMSB4X       -TMSB4X       Thymesin beta 4       -TMSB4X       -TMSAX	-17684	Integrin po	-VASP	Vasodilatator stimulated Porotein	-IFNG	Interferon commo	-SIAT1	Sigly transferase 1	
Gordex in 32       -KRT19       Keratine 19       Growth factor receptors : -GJA1       -DNMT1       DNA methyltransferase 1         -GJA1       Connexin 43       -TPM1       Tropomyosin 1       -ACLD1       Caldesmon 1       -DGFRA       PDGF receptor beta       -DNMT3       DNA methyltransferase 1         -GJA1       Connexin 43       -TPM1       Tropomyosin 1       -ACTN4       Actinin, alpha 4       -MC       -ACTN4       Actinin, alpha 4         -SNA1       Snail homolog 1       -TCALN       T-cell lyphoma invasion metastasis       -RET       HGF receptor       -HLA-C       -DNMT3       DNA methyltransferase 1         -SNA12       Snail homolog 1       -TLAN1       T-cell lyphoma invasion metastasis       -RET       -RET       -RET       -MC       -BET       -BET       -MC       -BET       -MC       -BET       -MC       -BET       -MC       -BET       -MC       -MC       -BET       -MC       -BET       -MC       -BET       -BET       -CET       -MC       -BET       -BET       -CET       -BET       -BET       -BET       -MC       -BET       -CAT       -MC       -MC       -MC	-6182	Connexin 26	-TMSB4X	Thymosin beta 4			-FRVWF1	Endogenous retroviral family W	
GJAS     Connexin 40     -CALD1     Caldesmon 1     -PDGFRA     PDFFRA     PDFFR PDFF receptor alpha     -DNMT3A     DNA methyltransferase 3, alpha       -GJAS     Connexin 40     -GALD1     Caldesmon 1     -PDGFRA     PDFFR PDFF receptor alpha     -DNMT3A     DNA methyltransferase 3, alpha       -GJAS     Connexin 43     -TVM1     Tropsmyosin 1     -MCT     -MCC     MHC (ass I, C     -HLA-C     MHC (ass I, C     -HLA-C     -HLA-C     MHC (ass I, C     -HLA-C     -HCC2     MHC (ass I, C     -HCC	-6781	Connexin 32	-KRT19	Keratine 19	Growth fo	cton necentons :	-DNMT1	DNA methyltransferase 1	
-GJA1     Connexin 43     -TPA1     Tropomyosin 1     -ACTN4     Actinin, alpha 4       -ACTN4     Actinin, alpha 4     -ME     -ME     -ME     -ME       -SNAI1     Snail homolog 1     -SNAI2     Snail homolog 2     -SUB     Tublini, beta polypeptide       -SNAI2     Snail homolog 2     (SLU6)       -STAI     Connexin 43     -TIAM1     T-cell lyphoma invasion metastasis       -SNAI2     Snail homolog 2     (SLU6)       -STAI     Snail homolog 2     -SUB       -STAI     Snail homolog 2     -SUB       -SNAI2     Snail homolog 2     -SUB       -TUN     jun porto-oncogene     -ACTN4       -TUN     jun porto-oncogene     -PRR6       -TUN     jun porto-oncogene     -PRR6       -TUN     jun porto-oncogene     -PR       -TUN     jun porto-oncogene     -FGR       -TUN     jun porto-oncogene     -FGR       -TUN     jun porto-oncogene     -FGR       -THR     Thyroid hormone receptor 2       -FR     -FGRR     -FGRR       -THRA     Thyroid hormone receptor 2       -FGR     -FGRR       -THRA     Thyroid hormone receptor 2       -FGRR     -GR2       -THRA     Thyroid hormone receptor 2	-6745	Connexin 40	-CALD1	Coldesmon 1	DDCED 4	DDCE acceptors :	-DNMT3A	DNA methyltransferase 3, alpha	
-ACTN4     Actinin, alpha 4       Transcription factors : -MCC     -ACTN4       -ACTN4     Actinin, alpha 4       -TUBB     Tubulin, beta polypeptide       -SNA12     Snail homolog 1       -SNA12     Snail homolog 1       -FXH4     E1A enhancer-binding protein       -CEBPA     CCAAT/enhancer binding protein       -CEBPA     CCAAT/enhancer binding protein       -CEBPA     CCAAT/enhancer binding protein       -TUN     jun B proto-oncogene       -JUND     jun D proto-oncogene       -JUND     jun D proto-oncogene       -THRA     Thread for receptor       -RER     Estrogen receptor       -ACKA     Retinoic X receptor alpha       -FSR2     Estrogen receptor 2       -JUND     jun D proto-oncogene       -JUND     -PGR       -JUND     jun D proto-oncogene       -JUND     -PGR       -HRA     Androgen receptor       -HRA     Androgen receptor       -HRA     Androgen receptor       -HRA     Androgen receptor       -JUNB     Jun D proto-oncogene       -JUNB     Jun D proto-oncogene       -JUNB     Jun D proto-oncogene       -HRA     Androgen receptor       -HRA     Androgen receptor       -HRA </td <td>-6741</td> <td>Connexin 43</td> <td>-TPM1</td> <td>Tropomyosin 1</td> <td>POGERA</td> <td>PDGF receptor alpha</td> <td>-DNMT3B</td> <td>DNA methyltransferase 3 beta</td>	-6741	Connexin 43	-TPM1	Tropomyosin 1	POGERA	PDGF receptor alpha	-DNMT3B	DNA methyltransferase 3 beta	
Transcription factors:       -TUBB       Tubulin, beta polypeptide       -MC       -MC       -HLA-C       MHC, class I, C         -MVC       c-Myc oncogene       -SMAII       Snail homolog 1       -TUAMI       T-cell lyphoma invasion metastasis       -HLA-C       MHC, class I, C       -HLA-C       MHC, class I, C         -SMAII       Snail homolog 1       -SMAII       Snail homolog 1       -SMAII       -SMAII       Stati Momolog 2 (SULG)       -HLA-C       MHC, class I, C       -EPHXI       Epoxide hydrolase 1 microsomal         -SMAII       Snail homolog 1       -SMAII       Snail homolog 1       -RAR       Retinoic acid receptor alpha       -RET       TESTB82       -erbb-2       -DNOS1       NHOS, neuronal nitric oxide synthase 1         -SCEPA       -TUNM       jun porto-oncogene       -PAR6       Peroxisome prolif activ. receptor 1       -F6FR1       Fibroblast growth factor receptor 1       -NOS3       ENOS, NOS3 (endorthelial)         -TUNM       jun D proto-oncogene       -F6R       Progenestrenon receptor 2       -HTR2       Serotanin 5 hydroxy-Trp receptor 4       -APOAI       -APOAI       -APOAI       -APOAI       -APOAI       -APOAI       -APOAI       -APOAI       -TER       -APOAI       -TER       -APOAI       -TER       -APA       Aphioporoteni A       -APA       -A	0071	Connexin 45	-ACTN4	Actinin, alpha 4	-PUGERD	HCE receptor beta	-PSMD10	Proteosome 265 subunit non-ATPose 10	
-MVC     c-Myc oncogene     -TIAM1     T-cell lyphoma invision metastasis     -RC1     RC1 oncogene     -BHX1     Epskie hydrolase 1 microsomal       -SNA12     Snail homolog 1     -TIAM1     T-cell lyphoma invision metastasis     -RT     Stem cell factor receptor     -BHX1     Epskie hydrolase 1 microsomal       -SNA12     Snail homolog 1     -RAR     Retinoic acid receptor alpha     -ERB8     -erbb-3     -HDAC1     Histone deacetylase 1       -CEIPA     EIA enhancer-binding protein     -RAR     Retinoic X receptor alpha     -ERB8     -erbb-3     -NOS3     NOS5, neuronal nitric oxid e synthase 1       -TUN     jun proto-oncogene     -PAR6     Peroxisome prolif activ. receptor 1     -F6FR1     Fibroblast growth factor receptor 1     -NOS3     ENOS, NOS3 (endothelial)       -TUND     jun D proto-oncogene     -PAR     Progen receptor 2     -HTR2B     Serotanin 5 hydroxy-Trp receptor 2     -NOS3     -NOS4     -NOS4     -NOS4     Alpha-2-macroglobulin       -TUND     jun D proto-oncogene     -PAR     Progen receptor 2     -HLAR     -HLAR     1Lb receptor     -REN     -REN     -REO1     -REO1     -REO2     -NOS3     -NOS3     ENOS, NOS3 (endothelial)       -TUND     jun D proto-oncogene     -F6R     -REO1     Lb receptor     -REO2     -NCA     -REO1     -RE	Transcript	ion factors :	-TUBB	Tubulin, beta polypeptide	-MEI	DET enceptor	-HLA-C	MHC class I C	
-M/C     C-Myc oncogene    KIA     Strem cell factor receptor    KIA    KIA     Strem cell factor receptor       -SNA11     Snail homolog 1    KIA     Nuclear receptors :    KIA	in unscript		-TIAM1	T-cell lyphoma invasion metastasis	-REI	RET oncogene	-EPHX1	Epoxide hydrolose 1 microsomol	
-SINAI2 Shall monolog 1 -SINAI2 Shall monolog 2 -SINAI2 Shall monolog 1 -SINAI2 Shall monolog 1 -RERB 2 -CACAT /Finholast growth factor receptor 1 -NOS, inductible hepatocycle NOS2A -NOS3 ENOS, NOS3 (endothelial) -HCFR Progesterone receptor 2 -JUND jun D proto-oncogene -JUND jun D proto-oncogene -JUND jun D proto-oncogene -JUND jun D proto-oncogene -JUNN Sin Brote receptor 2 -GR Progesterone receptor 2 -FGR Progesterone receptor 2 -JRR Natore receptor 4 -FR A natorgen receptor 2 -JLAR UP A receptor -THRB Thyroid hormone receptor bata -THRA Thyroid hormone receptor bata -GRBA GPot-Coupled receptor 54 (KISS) -GRBA GPOT-COUPLE Receptor	-MYC	c-myc oncogene			-KLI	Stem cell tactor receptor	-HDAC1	Histone deacetylase 1	
-SIVAL2 Shall nomolog 2 (SUO9) -TTV4 E1A enhancer-binding protein -CEPA CCAAT/enhancer binding protein -TTF1 Hepatic nuclear factor 1 (HNF1) -JUN jun proto-oncogene -JUNB jun B proto-oncogene -JUNB jun D proto-oncogene	-SINALL	Shall homolog 1	Nuclear	receptors :	-EUFR	COP receptor (ERDB1)	-MECP2	Methyl CoG binding protein 2	
-CEPPA CCART/enhancer-binding protein -CEPPA CCART/enhancer binding prot. a -TCF1 Hepatic nuclear factor 1 (HNF1) -TUN jun porto-oncogene -JUN jun D proto-oncogene -JUN jun D proto-oncogene -JUN jun D proto-oncogene -THR Thyroid hormone receptor 2 -THR Thyroid hormone receptor beta -THRA Thyroid hormone receptor beta -THRA Thyroid hormone receptor alpha	-SINALZ	Shall nomolog 2 (SLUG)	-DADA	Petinoic acid recentor alpha	-EKDD2	c-erbb-2	-NOS1	NNOS neuronal nitric axide synthese 1	
-CEPA CCAN remarker binding prof. at PARE Personal control of the participation factor receptor 1 -TCF1 Heparic nuclear factor 1 (HVF1) -TUNN jun proto-oncogene -JUND jun D proto-oncogene -JUND jun D proto-oncogene -THRB Thyroid hormone receptor beta -THRA Thyroid hormone receptor alpha -THRA Thyroid hormone receptor alpha -TH	-EIV4	CCAAT (when you hind in a sector	-DYDA	Petinoic X recentor alpha	-EKDD3	c-erbb-3	-NOS2A	iNOS inducible henotocyte NOS2A	
-TUN jun proto-oncogene -JUN jun D proto-oncogene -JUN jun D proto-oncogene -JUN jun D proto-oncogene -THRB Thyroid hormone receptor 2 -THRB Thyroid hormone receptor beta -THRA Thyroid hormone receptor alpha -THRA T	-CEDFA	Henetic nuclear factor 1 (HNE1)	-PP ARG	Peroxisome prolif activ recentor v	-ECED1	Eibnoblast anowth factor recentor 1	-NOS3	ENOS, NOS3 (endothelial)	
-JUNB jun B proto-oncogene -JUND jun D proto-oncogene -JUND jun D proto-oncogene -JUND jun D proto-oncogene -JUND jun D proto-oncogene -HRR Progesterone receptor 2 -HRR Thyroid hormone receptor beta -THRR Thyroid hormone receptor alpha -THRR Thyroid hormone receptor alpha -HRR Thyroid hormone rece		iun proto-oncogene	-ESR1	Estrogen receptor 1	-FGED2	Fibrablast anowth factor receptor 1	-A2M	Alpha-2-macroglobulin	
-JUND jun D proto-oncogene -JUND iun D proto-oncogene -AR Androgen receptor -HRB Thyroid hormone receptor beta -THRA Thyroid hormone receptor lapha -HRA Thyroid hormone receptor lapha -HCAR LG Sector - HLAR - PR54 -PR54 Gprot-coupled receptor 54 (KISSR) -GPR54 GProt-coupled receptor 54 (KISSR)		jun proto-oncogene	-ESD2	Estrogen receptor 2	-FOFR2	Fibrobiast growth tactor receptor 2	-HP	Hantoglobin	
-JUND jun D proto-oncogene -AR Androgen receptor bet -AR Androgen receptor bet -THRB Thyroid hormone receptor beta -THRA Thyroid hormone receptor alpha -THRA Thyroid hormone receptor alpha -GR2R IGF2 Receptor -LACR LD receptor -ZCR4 Chemokine (C-X-C) receptor 4 -GR2R IGF2 Receptor -LACR LD receptor -TERT Telomere reverse transcriptase	JUNB	jun o proto-oncogene	-PGP	Procesterone recentor	-TI 6D	TL6 receptor 2B	-APOA1	Apolipoprotein A-1	
-THRB Thyroid hormone receptor beta -THRA Thyroid hormone receptor alpha -GPR54 Gprot-coupled receptor 54 (KISSR) -IGF2R IGF2 Receptor -LHC6B LHC6P recentor	-30ND	jun o proto-oncogene	-AR	Androgen receptor		uPA receptor	-TERT	Telomere reverse transcriptase	
-THRA Thyroid hormone receptor alpha -THRA Thyroid hormone receptor alpha -GPR54 GProt-coupled receptor 54 (KISSR) -IGF2R IGF2 Receptor -LHC6R LHC6P recentor			-THRB	Thyroid hormone receptor beta	-CYCP4	Chemokine (C-X-C) recentor 4			
-IGF2R IGF2 Receptor -LHC6B LH/C6 recentor			-THRA	Thyroid hormone receptor alpha	-GPR54	Gnrat-counted recentor 54 (KTSSD)			
-UL/GB LUL/G recentor				apria	-TGE2B	IGE2 Recentor			
			-		-LHCGR	LH/CG receptor			

Fig. 2. List of the 240 genes studied.

#### Strategy of Analysis

First, two pools of five liver specimens from each group were respectively constituted by mixing aliquots of equivalent amounts of RNA from each of the liver samples. We then determined the mRNA expression level of the 240 genes in each pool. Genes whose expression differed between pools by at least three-fold in group B versus group A were selected. This robust selection criterion ensures the identification of genes of marked interest.

The expression level of these selected genes was then assessed in each of the 28 individual samples. Comparison of the pool values with the mean individual values showed that RNA pooling was an appropriate initial screening approach, significantly limiting the required number of PCR experiments. Using the same approach, we have previously shown the involvement of several altered molecular pathways in the genesis of hepatitis C virus (HCV) infection,<sup>4</sup> breast cancer,<sup>14</sup> and hepatitis C liver fibrosis.<sup>5</sup>

#### Statistical Analysis

Relationships between the molecular markers and histological parameters (in both group A and group B and in chronic hepatitis C) were tested using the nonparametric Mann-Whitney U test.<sup>15</sup> Differences between the two populations were judged significant at confidence levels above 95% (P < 0.05). To visualize the capacity of a given molecular marker to discriminate between two populations (in the absence of an arbitrary cutoff value), we summarized the data in a receiver operating characteristic (ROC) curve.<sup>16</sup>

The mRNA levels indicated in Tables 1 and 2 (calculated as described in Materials and Methods) show the abundance of the target relative to the endogenous control (*TBP*) to normalize the starting amount and quality of total RNA. Similar results were obtained with a second endogenous control, *RPLP0* (also known as 36B4) (data not shown).

## Results

*mRNA Expression of the 240 Genes in the Group B Pool Sample Relative to the Group A Pool Sample.* The mean *TBP* gene Ct (threshold cycle) values for the

# Table 1. Significantly Dysregulated Genes in Surgical Nontumoral Liver Patients Relative to Percutaneous Normal Liver Patients

Gene Symbols	Alternate Symbols	Gene Name	Gene Characterization	Percutaneous Normal Liver (n = 14)	Surgical Nontumoral Liver (n = 14)	P Value*	ROC- AUC
Significant	tly up-regulated ge	nes in surgical nontumoral liver patients					
PAI1	SERPINE1	Plasminogen activator inhibitor-1	Extracellular matrix	1.0 (0.2-3.6)†	29.7 (9.5-83.9)	0.0000067	1.000
THBS1	TPS1	Thrombospondin-1	Extracellular matrix	1.0 (0.3-1.9)	12.4 (5.6-81.2)	0.0000067	1.000
IL8		Interleukin-8	Growth factor/cytokine	1.0 (0.6-2.1)	97.9 (3.8-434.7)	0.0000067	1.000
PTGS2	COX2	Prostaglandin-endoperoxide synthetase-2	Angiogenesis	1.0 (0.4-1.4)	11.1 (2.5-40.7)	0.0000067	1.000
CXCR4		Chemokine (C-X-C motif) receptor-4	Growth factor receptor	1.0 (0.3-1.6)	5.9 (2.1-19.4)	0.0000067	1.000
JUN		Jun oncogene	Transcription factor	1.0 (0.2-1.9)	14.0 (3.7-22.5)	0.0000067	1.000
FOS		Fos oncogene	Transcription factor	1.0 (0.3-14.8)	57.9 (23.3-220.9)	0.0000067	1.000
CCL2	MCP-1	Chemokine (C-C motif) ligand-2	Growth factor/cytokine	1.0 (0.5-2.3)	13.6 (1.2-40.1)	0.000014	0.982
SOCS3	SSI-3	Suppressor of cytokine signaling- 3 (SSI-3)	Signal transduction	1.0 (0.2-2.4)	28.5 (1.2-71.9)	0.000035	0.959
CXCL1	GRO1	Chemokine (C-X-C motif) ligand-1	Growth factor/cytokine	1.0 (0.4-2.2)	9.2 (0,9-56.0)	0.000043	0.954
HIF1A		Hypoxia-inducible factor-1, alpha	Angiogenesis	1.0 (0.4-1.5)	2.5 (1.1-6.1)	0.000053	0.949
MMP9		Matrix metalloproteinase-9	Extracellular matrix	1.0 (0.3-6.0)	15.0 (0.8-74.2)	0.000094	0.934
CTGF		Connective tissue growth factor	Growth factor/cytokine	1.0 (0.1-4.6)	5.4 (0.7-16.8)	0.00020	0.913
HAS2		Hyaluronan synthase-2	Extracellular matrix	1.0 (0.5-2.1)	11.0 (0.1-41.8)	0.00024	0.908
IL6		Interleukin-6	Growth factor/cytokine	1.0 (0.3-7.9)	58.9 (0.2-338.9)	0.00048	0.888
EGR1	KROX-24	Early growth response-1 (KROX-24)	Transcription factor	1.0 (0.2-16.4)	7.1 (2.9-18.9)	0.00048	0.888
CCL3	MIP-1A	Chemokine (C-C motif) ligand-3 (MIP-1A)	Growth factor/cytokine	1.0 (0.5-4.0)	6.7 (0.5-21.5)	0.00048	0.888
CCL4	MIP-1B	Chemokine (C-C motif) ligand-4 (MIP-1B)	Growth factor/cytokine	1.0 (0.3-2.4)	2.9 (0.3-10.3)	0.0028	0.832
PAI2	SERPINB2	Plasminogen activator inhibitor-2	Extracellular matrix	1.0 (0.0-11.4)	26.7 (0.0-165.2)	0.0035	0.824
CDKN1A	P21	Cyclin-dependent kinase inhibitor 1A (p21 protein)	Cell cycle regulation	1.0 (0.2-3.4)	2.7 (0.5-9.3)	0.0041	0.819
LIF		Leukemia inhibitory factor	Growth factor/cytokine	1.0 (0.3-4.2)	5.1 (0.3-17.5)	0.0051	0.811
CRP		C-reactive protein	Hepatic secretory protein	1.0 (0.3-14.1)	14.9 (0.4-132.8)	0.0067	0.801
MMP2		Matrix metalloproteinase-2	Extracellular matrix	1.0 (0.4-3.0)	1.9 (0.6-24.0)	0.039	0.730
CXCL5	ENA78	Chemokine (C-X-C motif) ligand-5	Growth factor/cytokine	1.0 (0.1-18.6)	3.5 (0.3-143,8)	NS	0.702
COL1A2		Collagen, type I, alpha-2	Extracellular matrix	1.0 (0.5-2.9)	1.1 (0.1-42.5)	NS	0.594
IL1A		Interleukin 1, alpha	Growth factor/cytokine	1.0 (0.0-4.4)	0.9 (0.0-13.0)	NS	0.582
COL1A1		Collagen, type I, alpha-1	Extracellular matrix	1.0 (0.0-2.6)	0.8 (0.4-86.4)	NS	0.467
Significant	tly down-regulated	genes in surgical nontumoral liver patients					
IHH		Indian hedgehog homolog	Growth factor/cytokine	1.0 (0.28-2.01)	0.06 (0.01-0.20)	0.0000067	0.000
GPT		Alanine aminotransferase	Metabolic enzyme	1.0 (0.31-2.78)	0.38 (0.07-1.29)	0.00048	0.112
IREG1	SLC11A3, HFE4	Ferroportin-1	Iron metabolism	1.0 (0.55-1.72)	0.54 (0.21-1.66)	0.003	0.171
CYP2E1		Cytochrome P450 CYP2E1	Metabolic enzyme	1.0 (0.49-2.47)	0.69 (0.30-1.48)	NS	0.283
GFAP		Glial fibrillary acidic protein	Cytoskeletal	1.0 (0.34-8.94)	0.45 (0.22-14.94)	NS	0.298

Abbreviations: AUC, area under the curve analysis; NS, not significant; ROC, receiver operating characteristics.

\*Mann-Whitney U test.

†Median (range) of gene mRNA levels.

group A pool and the group B pool were  $25.23 \pm 0.24$  and  $25.43 \pm 0.23$ , respectively.

Seven (2.9%) of the 240 genes were detectable but not reliably quantifiable in both the group B and group A pools (Ct > 32). The mRNA expression of 32 (13.7%) of the remaining 233 genes showed at least a three-fold difference between the two pools; 27 (84.4%) genes were up-regulated and 5 (15.6%) were down-regulated in the group B pool sample compared with the goup A pool sample.

*mRNA Expression of the 32 Dysregulated Genes in 14 Group B Samples and 14 Group A Samples.* The expression level of the 32 dysregulated genes identified via pooled sample analysis was then determined individually in the 14 group B samples and 14 group A samples. Twenty-three (85.2%) of the 27 up-regulated genes identified by pooled sample analysis were significantly up-regulated in the 14 group B samples compared with the 14 group A samples (P < 0.05; Table 1). Three (60%) of the five down-regulated genes identified via pooled sample analysis were significantly down-regulated in the 14 group B samples compared with the 14 group A samples (P < 0.05; Table 1).

The 23 up-regulated genes mainly encoded proteins involved in immune response (interferon pathway, growth factor, growth factor receptor, cytokine: *IL8*, *CXCR4*, *CCL2*, *CXCL1*, *IL6*, *CCL3*, *CCL4*, *LIF*, *CXCL5*, *IL1A*); and matrix remodeling (angiogenesis, extracellular matrix, extracellular matrix protease, inhibitors of matrix

# Table 2. Genes Perfectly Discriminated Between Percutaneous Normal Liver and Surgical Nontumoral Liver Patients According to Nature of the Adjacent Tumor (Benign Versus Malignant) in the Surgical Nontumoral Group

Gene Symbols	Alternate Gene Symbols Name Chara		Gene Characterization	Percutaneous Surgical Normal Liver Nontumoral (n = 14) (n = 14)		Surgical Nontumoral Liver Patients Adjacent to Benign (n = 7)	Surgical Nontumoral Liver Patients Adjacent to Malignant (n = 7)	P Value*	ROC- AUC
Genes up	-regulated i	n surgical nontumora	al liver patients						
PAI1	SERPINE1	Plasminogen activator inhibitor-1	Extracellular matrix	1.0 (0.2-3.6)†	29.7 (9.5-83.9)	19.0 (9.5-83.9)	31.1 (9.6-46.5)	NS	0.633
THBS1	TPS1	Thrombospondin-1	Extracellular matrix	1.0 (0.3-1.9)	12.4 (5.6-81.2)	7.6 (5.6-81.2)	19.9 (9.4-25.7)	NS	0.816
IL8		Interleukin-8	Growth factor/ cytokine	1.0 (0.6-2.1)	97.9 (3.8-434.7)	80.1 (11.7-434.7)	115.7 (3.8-381.1)	NS	0.388
PTGS2	COX2	Prostaglandin- endoperoxide synthetase-2	Angiogenesis	1.0 (0.4-1.4)	11.1 (2.5-40.7)	12.9 (5.5-34.4)	9.3 (2.5-40.7)	NS	0.816
CXCR4		Chemokine (C-X-C motif) receptor- 4	Growth factor receptor	1.0 (0.3-1.6)	5.9 (2.1-19.4)	6.0 (2.1-12.4)	4.2 (2.4-19.4)	NS	0.490
JUN		Jun oncogene	Transcription factor	1.0 (0.2-1.9)	14.0 (3.7-22.5)	13.1 (6.2-21.5)	14.9 (3.7-22.5)	NS	0.510
FOS		Fos oncogene	Transcription factor	1.0 (0.3-14.8)	57.9 (23.3-220.9)	69.0 (23.3-220.9)	38.6 (29.6-111.3)	NS	0.388
Genes down-regulated in surgical nontumoral liver patients									
IHH		Indian Hedgehog homolog	Growth factor/ cytokine	1.0 (0.28-2.01)	0.06 (0.01-0.20)	0.07 (0.02-0.20)	0.06 (0.01-0.16)	NS	0.378

Abbreviations: AUC, area under the curve analysis; NS, not significant; ROC, receiver operating characteristics.

\*Mann -Whitney U test (venign versus malignant).

†Median (range) of gene mRNA levels.

# protease: *PAI1*, *THBS1*, *PTGS2*, *HIF1A*, *MMP9*, *CTGF*, *HAS2*, *PAI2*, *MMP2*, and *COL1A1*).

The capacity of each of these 26 dysregulated genes (23 up-regulated and 3 down-regulated) to discriminate between group B and group A samples was then tested via ROC curve analysis. The overall diagnostic values of the 26 molecular markers were assessed in terms of their area under the curve (AUC) values (Table 1).

Eight genes perfectly discriminated between groups A and B (AUC-ROC, 1.000): seven up-regulated genes (*PAI1, THBS1, IL8, PTGS2, CXCR4, JUN,* and *FOS*) and one down-regulated gene (*IHH*). Fig. 3 shows the mRNA levels of three of these genes (*PAI1, THBS1,* and *IHH*) in each of the 14 group B samples and the 14 group A samples.

Among the eight genes that discriminated perfectly between the group B and group A samples, there was no significant difference in samples from group B when they were compared for the nature (that is, benign or malignant) of the distant tumor (Table 2).

mRNA Expression of IL8 in Different Stage of Chronic Hepatitis C in Comparison with Group B Samples and Group A Samples. To determine whether the choice of histologically normal controls could lead to discordance or misinterpretation of specific pathological conditions such as chronic hepatitis C, we measured one (*IL8*) of the eight perfectly discriminating genes in five series of various grades of necroinflammation and stages of liver fibrosis (A1F1, A2F1, A1F2, A2F2, A2F3).

*IL8* was investigated because it has been shown in culture cells that the HCV nonstructural 5A protein induces *IL8*.<sup>17</sup> *IL8* mRNA expression increases from mild chronic hepatitis C (A1F1) to severe liver lesions (A2F3) (Fig. 4). The results show an underexpression or overexpression of specific genes (such as *IL8*) in HCV infection depending on whether the controls were obtained percutaneously or surgically. It is interesting to note that in this example, group A seems to be the more appropriate control, because an increase in *IL8* mRNA levels from mild (A1F1) to advanced disease (A2F3) is observed, suggesting a model with *IL8* activation during fibrogenesis.

*mRNA Expression of Other Genes Involved in the Hedgehog-Gli Signaling Pathway in Group B and Group A Samples.* The only down-regulated gene that perfectly discriminated between groups A and B (*IHH*) is involved in the Hedgehog-Gli signaling pathway. To further explore the Hedgehog-Gli signaling pathway to discriminate between groups A and B, we tested the expression of six additional genes involved in this pathway (*DHH, SHH, GLI1, GLI2, GLI3,* and *GLI4*) in three



Fig. 3. Shown are the mRNA levels of three perfectly discriminatory genes (*PAI1*, *THBS1*, *IHH*) in the 14 percutaneous normal liver samples and the 14 surgical nontumoral liver samples. The median value (range) is indicated for each subgroup. NL, normal liver.

high *IHH*-expressing percutaneous normal liver samples and three low *IHH*-overexpressing surgical nontumoral liver samples. The results are summarized in Fig. 5. *DHH* transcripts were detectable but not reliably quantifiable in



Fig. 4. *IL8* expression in different grade of necroinflammation and stage of fibrosis in chronic hepatitis C as compared with group B or group A.



Fig. 5. Expression level of Hedgehog/Gli genes in three high *IHH*-expressing percutaneous normal liver samples and three low *IHH*-expressing surgical nontumoral liver samples. NL, normal liver.

both the group B and group A samples (Ct > 32). Total positive associations (AUC-ROC, 1.000) were found between *IHH* and three of the five expressed genes (*SHH*, *GLI1*, and *GLI4*).

# Discussion

Gene expression profiling technologies are used to analyze gene networks whose expression is associated with specific pathological conditions compared with normal tissue.<sup>1</sup> Generally, normal tissue for normal controls is obtained in various ways, including percutaneous and surgical biopsy.<sup>1-2,5,18</sup>

This study focused on the gene expression changes observed in the histologically normal liver in relation to the sampling method (percutaneous or surgical liver biopsy). We analyzed the gene transcriptional profiles of percutaneous normal liver specimens, obtained under local anesthesia from 14 adults with mildly elevated serum alanine aminotransferase activity in whom all causes of liver disease had been ruled out (medication, alcohol, chronic viral hepatitis, autoimmune processes, and metabolic disease) compared with nontumoral liver biopsies obtained from 14 adults during surgery for liver metastasis of colorectal cancer or benign liver tumors. All 28 liver tissue specimens (groups A and B) were histologically normal. For our study, we selected liver samples based on a histological normal aspect carefully analyzed by two liver pathologists.

The 26 genes that were significantly dysregulated (23 up-regulated and three down-regulated) in the group B samples mainly encoded proteins involved in immune response (interferon pathway, growth factor, growth factor receptor, cytokine: *IL8*, *CXCR4*, *CCL2*, *CXCL1*, *IL6*, *CCL3*, *CCL4*, *LIF*) and matrix remodeling (angiogenesis, extracellular matrix, extracellular matrix protease, inhibitors of matrix protease: *PAI1*, *THBS1*, *PTGS2*, *HIF1A*, *MMP9*, *CTGF*, *HAS2*, *PAI2*, and *MMP2*). The gene up-regulations in the surgical nontumoral biopsies were not due to tumor cell contamination or stroma cell activation, because similar expression levels were observed in the normal liver samples associated with distant malignant tumors compared with those associated with distant benign tumors.

Most of these genes belong to the acute phase response family and are up-regulated after "stress."19 All living organisms need to sense and respond to conditions that stress their homeostatic mechanisms. The liver plays a central role in the body's response to injury.<sup>20</sup> Expression of hepatic acute-phase and heat-shock genes probably contributes to restoring homeostasis after surgical procedures. Activation of the acute phase response can be due to different causes, such as hypoxemia, infection, surgery, and anesthesia. The acute phase response gene family includes and/or interacts with numerous family genes (inflammation, cytokines, extracellular matrix, and so forth). Systemic stressors can lead to regeneration.<sup>12</sup> Hypoxia—a reduction in the normal level of tissue oxygen tension occurs during acute and chronic vascular diseases, pulmonary disease and cancer.<sup>21</sup> Another type of hypoxia known as acute or perfusion-limited hypoxia occurs when aberrant blood vessels are shut down, which also causes a reverse in blood flow. Closed vessels can be reopened, leading to reperfusion of hypoxic tissue with oxygenated blood. This leads to an increase in free radical concentrations, tissue damage, and activation of stress-response genes-a process known as reoxygenation injury. It should be noted that dysregulation of *HIF1A*, a gene playing a major role in hypoxia, was observed in this study.

What about surgical liver biopsies under general anesthesia? General anesthetics are known to transiently increase expression of mRNAs of immediate-early genes in the brain.<sup>22</sup> Furthermore, anesthesia has been shown to mimic ischemic preconditioning,<sup>23</sup> the process by which brief exposure to ischemia provides robust protection or tolerance against the injurious effects of longer-term ischemia via expression of acute phase response genes.

Among the 26 dysregulated genes identified in this study, eight perfectly discriminated between groups A and B (AUC-ROC, 1.000): seven up-regulated genes (*PAI1, THBS1, PTGS2, CXCR4, JUN, FOS,* and *IL8*) all involved in the acute phase response, and one down-regulated gene (*IHH*) that codes one of the three mammalian Hedgehog (Hh) proteins playing a major role in vertebrate development and tumorigenesis.

THBS1, PAI1. THBS1 and PAI1 code molecules involved in matrix turnover. Thrombospondins form a family of secreted glycoproteins with pleiotropic functions and widespread expression.<sup>24-26</sup> THBS1 is involved in the regulation of cellular responses to injury. It has been shown that THBS1 acts as a strong promoter of transforming growth factor  $\beta$  effects in hepatic stellate cells.<sup>27</sup> Plasminogen activator inhibitor-1 (PAI-1) is the main physiological inhibitor of both the urokinase-type plasminogen activator and the tissue plasminogen activator and thereby plays an important role in regulation of the fibrinolytic system. PAI-1 has also been reported to act as an acute phase protein,28 and plasma PAI-1 levels rise markedly during disease states often associated with an acute phase response, including trauma, surgical procedures, and burn injury. The inflammatory response is a nonspecific reaction of the human body to trauma, injury, or infection, and the liver is a major site for synthesis of inflammatory and procoagulant mediators, including Creactive protein, fibrinogen, interleukin-6, and PAI-1.29

*CXCR4, IL8, and PTGS2. CXCR4, IL8*, and *PTGS2* code molecules involved in angiogenesis and inflammation.

Stromal cell–derived factor-1 is a member of the C-X-C motif (CXC) chemokine family that binds to the seven-span transmembrane G-protein–coupled CXCR4 receptor, which has stromal cell–derived factor-1 as its unique ligand.<sup>30</sup> CXCR4 is expressed by most leukocyte populations, endothelial cells, as well as epithelial and carcinomatous cells. In a recent study, hepatic regeneration was induced by treating rats with 2-acetylaminofluorene and followed by partial hepatectomy.<sup>31</sup> CXCR4 mRNA expression, assessed by both quantitative RT-PCR and *in situ* hybridization, was increased during hepatic regeneration.

*PTGS2*, also called *COX-2*, plays an important role in tumor and endothelial cell biology. Increased expression of *PTGS2* occurs in multiple cells within the tumor microenvironment, which can affect angiogenesis. *PTGS2* appears to play a key role in the release and activity of proangiogenic proteins.<sup>32</sup>

Interleukin-8, a cytokine of the CXC chemokine family, plays an important role in tumor progression and metastasis in a variety of human cancers, including lung cancers.<sup>33</sup> Interleukin-8 biological activity in tumors and the tumor microenvironment may contribute to tumor progression through its potential function in the regulation of angiogenesis, cancer cell growth and survival, tumor cell motion, leukocyte infiltration, and modification of immune responses.

*IL8* mRNA expression increases from mild chronic hepatitis C (A1F1) to severe liver lesions (A2F3). In prior immunohistochemical studies of HCV infection, IL8 protein was shown to be expressed in infiltrating cells in the portal tract and fibrotic septa and within hepatic lobules in patients.<sup>34</sup> We have previously reported that there was a correlation between intrahepatic mRNA *IL8* expression and hepatic fibrosis in HCV patients.<sup>5</sup> Moreover, exposure of human umbilical vein endothelial cells to HCV-like particles resulted in increased IL8 production.<sup>35</sup>

**JUN, FOS.** The AP-1 transcription factor is mainly composed of Jun, Fos, and/or ATF protein heterodimers. AP-1 mediates gene regulation in response to a plethora of physiological and pathological stimuli, including cytokines, growth factors, stress signals, and bacterial and viral infections, as well as oncogenic stimuli.<sup>36</sup> Interestingly, a rat model after portal branch ligation produced atrophy of the deprived lobes (70% of the liver parenchyma), whereas the perfused lobes undergo compensatory regeneration; c-fos and c-jun expression were elevated during the first 2 hours in all the compartments.<sup>37</sup> These findings suggest that the cellular and molecular changes that occur early in a regenerating liver are nonspecific, possibly stress-induced cellular responses. They do not indicate future progression toward atrophy or regeneration.

IHH and the Mammalian Hedgebog Proteins. Among the 26 dysregulated genes, we identified eight that perfectly discriminated between group A and group B (AUC-ROC, 1.000), one of which is a down-regulated gene (IHH) that codes one of the three mammalian Hedgehog (Hh) proteins. Alteration of this unexpected pathway was confirmed via identification of an alteration of additional genes involved in this signaling pathway (one additional ligand [SHH] and two transcriptional factors [GLI1] and [GLI4]). The Hh pathway has been shown to direct the fate of neural and myofibroblastic cells during embryogenesis and during tissue remodeling in adults.<sup>38-39</sup> Recent studies suggest a major role for the Hh pathway in hepatic stellate cell activation and viability<sup>40</sup> and in the maintenance of hepatic progenitors during fetal development and adulthood.<sup>41</sup> Fatty liver injury alters Hh activity in liver progenitors, and this might promote epithelial–mesenchymal transitions that result in liver fibrosis.<sup>42</sup> Hh dysregulation is also observed in human hepatocarcinogenesis.<sup>43</sup> Our results regarding Hh signaling could suggest qualitative or quantitative variations in hepatic stellate cells and/or hepatic progenitors between percutaneous and surgical normal liver tissues.

This study demonstrates that histologically normal liver tissue obtained in two different ways (percutaneous or surgical liver biopsy) has different gene expression patterns, though all specimens are histologically normal. The most notable changes in gene expression mainly occurred in the inflammatory response gene family. Therefore, this study emphasizes the importance of an adequate selection of histologically normal controls to prevent discordant or false results in gene expression profile analysis.

It is difficult to state which is the best histologically normal control. In any study, the appropriate histological normal control should be obtained in the same technical way as the pathological sample. For instance, in a study of chronic hepatitis C in which liver samples are obtained percutaneously, the histologically normal samples should be obtained through percutaneous liver biopsy.<sup>4-6</sup> In all cases, the controls used should be clearly described. Finally, the careful selection of controls is crucial, since the wrong selection could lead to misinterpretation of results.

## References

- 1. Whitfield ML, George LK, Grant GD, Perou CM. Common markers of proliferation. Nat Rev Cancer 2006;6:99-106.
- Perou CM, Jeffrey SS, van de Rijn M, Rees CA, Eisen MB, Ross DT, et al. Distinctive gene expression patterns in human mammary epithelial cells and breast cancers. Proc Natl Acad Sci U S A 1999;96:9212-9217.
- DeRisi J, Penland L, Brown PO, Bittner ML, Meltzer PS, Ray M, et al. Use of a cDNA microarray to analyse gene expression patterns in human cancer. Nat Genet 1996;14:457-460.
- Bieche I, Asselah T, Laurendeau I, Vidaud D, Degot C, Paradis V, et al. Molecular profiling of early stage liver fibrosis in patients with chronic hepatitis C virus infection. Virology 2005;332:130-144.
- Asselah T, Bieche I, Laurendeau I, Paradis V, Vidaud D, Degott C, et al. Liver gene expression signature of mild fibrosis in patients with chronic hepatitis C. Gastroenterology 2005;129:2064-2075.
- Asselah T, Bieche I, Narguet S, Sabbagh A, Laurendeau I, Ripault MP, et al. Liver gene expression signature to predict response to pegylated interferon plus ribavirin combination therapy in patients with chronic hepatitis C. Gut. 2008;57:516-524.
- Foti M, Granucci F, Ricciardi-Castagnoli P. A central role for tissueresident dendritic cells in innate responses. Trends Immunol 2004;25:650-654.
- Staros EB. Innate immunity: new approaches to understanding its clinical significance. Am J Clin Pathol 2005;123:305-312.
- 9. Haller O, Kochs G, Weber F. The interferon response circuit: induction and suppression by pathogenic viruses. Virology 2006;344:119-130.
- Leask A, Abraham DJ. TGF-beta signaling and the fibrotic response. FASEB J 2004;18:816-827.
- Friedman SL. Hepatic stellate cells: protean, multifunctional, and enigmatic cells of the liver. Physiol Rev 2008;88:125-172.
- 12. Fausto N. Involvement of the innate immune system in liver regeneration and injury. J Hepatol 2006;45:347-349.

- Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. HEPATOLOGY 1996;24:289-293.
- 14. Tozlu S, Girault I, Vacher S, Vendrell J, Andrieu C, Spyratos F, et al. Identification of novel genes that co-cluster with estrogen receptor alpha in breast tumor biopsy specimens, using a large-scale real-time reverse transcription-PCR approach. Endocr Relat Cancer 2006;13:1109-1120.
- Mann H, Whitney D. On a test of whether one or two random variables is stochastically larger than the other. Ann Math Stat 1947;18:50-60.
- Didier G, Brezellec P, Remy E, Henaut A. GeneANOVA—gene expression analysis of variance. Bioinformatics 2002;18:490-491.
- Polyak SJ, Khabar KS, Paschal DM, Ezelle HJ, Duverlie G, Barber GN, et al. Hepatitis C virus nonstructural 5A protein induces interleukin-8, leading to partial inhibition of the interferon-induced antiviral response. J Virol 2001;75:6095-6106.
- Asselah T, Bièche I, Paradis V, Bedossa P, Vidaud M, Marcellin P. Genetics, genomics, and proteomics: implications for the diagnosis and the treatment of chronic hepatitis C. Semin Liver Dis 2007;27:13-27.
- Murray JI, Whitfield ML, Trinklein ND, Myers RM, Brown PO, Botstein D. Diverse and specific gene expression responses to stresses in cultured human cells. Mol Biol Cell 2004;15:2361-2374.
- Pannen BH, Maeda K, Ayuse T, Brienza N, Revelly JP, Robotham JL, et al. Hepatic heat shock and acute-phase gene expression are induced simultaneously after celiotomy in the anesthetized pig. Anesthesiology 1995;83: 850-859.
- Harris AL. Hypoxia—a key regulatory factor in tumour growth. Nat Rev Cancer 2002;2:38-47.
- 22. Hamaya Y, Takeda T, Dohi S, Nakashima S, Nozawa Y. The effects of pentobarbital, isoflurane, and propofol on immediate-early gene expression in the vital organs of the rat. Anesth Analg 2000;90:1177-1183.
- Kersten JR, Schmeling TJ, Pagel PS, Gross GJ, Warltier DC. Isoflurane mimics ischemic preconditioning via activation of K(ATP) channels: reduction of myocardial infarct size with an acute memory phase. Anesthesiology 1997;87:361-370.
- Bornstein P. Thrombospondins as matricellular modulators of cell function. J Clin Invest 2001;107:929-934.
- 25. Good DJ, Polverini PJ, Rastinejad F, Le-Beau MM, Lemons RS, Frazier WA, et al. A tumor suppressor-dependent inhibitor of angiogenesis is immunologically and functionally indistinguishable from a fragment of thrombospondin. Proc Natl Acad Sci U S A 1990;87:6624-6628.
- 26. Watnick RS, Cheng YN, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell 2003;3:219-231.
- Breitkopf K, Sawitza I, Westhoff JH, Wickert L, Dooley S, Gressner AM. Thrombospondin 1 acts as a strong promoter of transforming growth factor beta effects via two distinct mechanisms in hepatic stellate cells. Gut 2005;54:673-681.
- 28. Renckens R, Roelofs JJ, de Waard V, Florquin S, Lijnen HR, Carmeliet P, et al. The role of plasminogen activator inhibitor type 1 in the inflamma-

tory response to local tissue injury. J Thromb Haemost 2005;3:1018-1025.

- Castell JV, Gomez MJ, David M, Fabra R, Trullenque R, Heinrich PC. Acute-phase response of human hepatocytes: Regulation of acute-phase protein synthesis by interleukin-6. HEPATOLOGY 1990;12:1179-1186.
- Murdoch C. CXCR4: chemokine receptor extraordinaire. Immunol Rev 2000;177:175-184.
- Mavier P, Martin N, Couchie D, Preaux AM, Laperche Y, Zafrani ES. Expression of stromal cell-derived factor-1 and of its receptor CXCR4 in liver regeneration from oval cells in rat. Am J Pathol 2004;165:1969-1977.
- Gately S, Kerbel R.Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. Prog Exp Tumor Res 2003;37:179-192.
- Yuan A, Chen JJ, Yao PL, Yang PC. The role of interleukin-8 in cancer cells and microenvironment interaction. Front Biosci 2005;10:853-865.
- 34. Koziel MJ, Dudley D, Afdhal N, Grakoui A, Rice CM, Choo QL, et al. HLA class I-restricted cytotoxic T lymphocytes specific for hepatitis C virus. Identification of multiple epitopes and characterization of patterns of cytokine release. J Clin Invest 1995;96:2311-2321.
- Balasubramanian A, Munshi N, Koziel MJ, Hu Z, Liang TJ, Groopman JE, et al. Structural proteins of hepatitis C virus induce interleukin 8 production and apoptosis in human endothelial cells. J Gen Virol 2005; 86:3291-3301.
- Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci 2004;117:5965-5973.
- 37. Starkel P, Horsmans Y, Sempoux C, De Saeger C, Wary J, Lause P, et al. After portal branch ligation in rat, nuclear factor kappaB, interleukin-6, signal transducers and activators of transcription 3, c-fos, c-myc, and c-jun are similarly induced in the ligated and nonligated lobes. HEPATOLOGY 1999;29:1463-1470.
- Taipale J, Beachy PA. The Hedgehog and Wnt signalling pathways in cancer. Nature 2001;411:349-354.
- Van Den Brink GR, Bleuming SA, Hardwick JC, Schepman BL, Offerhaus GJ, Keller JJ, et al. Indian Hedgehog is an antagonist of Wnt signaling in colonic epithelial cell differentiation. Nat Genet 2004;36:277-282.
- Sicklick JK, Li YX, Choi SS, Qi Y, Chen W, Bustamante M, et al. Role for hedgehog signaling in hepatic stellate cell activation and viability. Lab Invest 2005;85:1368-1380.
- Sicklick JK, Choi SS, Bustamante M, McCall SJ, Pérez EH, Huang J, et al. Evidence for epithelial-mesenchymal transitions in adult liver cells. Am J Physiol Gastrointest Liver Physiol 2006;291:G575-G583.
- 42. Fleig SV, Choi SS, Yang L, Jung Y, Omenetti A, VanDongen HM, et al. Hepatic accumulation of Hedgehog-reactive progenitors increases with severity of fatty liver damage in mice. Lab Invest 2007;87:1227-1239.
- Sicklick JK, Li YX, Jayaraman A, Kannangai R, Qi Y, Vivekanandan P, et al. Dysregulation of the Hedgehog pathway in human hepatocarcinogenesis. Carcinogenesis 2006;27:748-757.